2023-03-31 00:50:36 ET
- Sutro Biopharma press release ( NASDAQ: STRO ): FY GAAP EPS of -$2.35 beats by $0.16 .
- Revenue of $67.8M (+9.6% Y/Y) misses by $0.57M .
- As of December 31, 2022, Sutro had cash, cash equivalents and marketable securities of $302.3 million, as compared to $287.3 million as of September 30, 2022, and approximately 0.7 million shares of Vaxcyte common stock with a fair value of $32.0 million, which together provide a projected cash runway into the second half of 2024, based on current business plans and assumptions.
For further details see:
Sutro Biopharma GAAP EPS of -$2.35 beats by $0.16, revenue of $67.8M misses by $0.57M